Featured Article

Familial Hypercholesterolemia: An Underdiagnosed Disease Gets a Second Look

Familial Hypercholesterolemia: An Underdiagnosed Disease Gets a Second Look

Despite the frequency with which it occurs, familial hypercholesterolemia often goes undiagnosed, with only 10% of affected patients aware of this genetic disorder.

Latest Features

Familial Hypercholesterolemia: An Underdiagnosed Disease Gets a Second Look

Familial Hypercholesterolemia: An Underdiagnosed Disease Gets a Second Look

Despite the frequency with which it occurs, familial hypercholesterolemia often goes undiagnosed, with only 10% of affected patients aware of this genetic disorder.

PCSK9 Inhibition: Benefits Outweigh Risks in Patients With Diabetes

PCSK9 Inhibition: Benefits Outweigh Risks in Patients With Diabetes

Statin therapy is the first line of defense against high LDL-C and the risk for atherosclerotic cardiovascular disease, the leading cause of morbidity and mortality in individuals with diabetes.

Nutraceuticals May Benefit Patients Who Are Statin Intolerant

Nutraceuticals May Benefit Patients Who Are Statin Intolerant

Nutraceuticals may offer a solution to patients who cannot tolerate statins because of severe muscle pain.

Breathing New Life Into COPD and Asthma Therapy With Statins

Breathing New Life Into COPD and Asthma Therapy With Statins

Statins have anti-inflammatory and anti-oxidative effects, which could reduce exacerbations of both asthma and chronic obstructive pulmonary disease.

FOURIER Trial Data Questions: Are PCSK9 Inhibitors The Right Choice?

FOURIER Trial Data Questions: Are PCSK9 Inhibitors The Right Choice?

Results of the FOURIER trial, presented at the 2017 ACC Scientific Sessions, raise questions about the efficacy of PCSK9 inhibitors as long-term therapy for patients with atherosclerotic CVD.

PCSK9 Inhibitor Alirocumab Associated With 75% Reduction in Apheresis

PCSK9 Inhibitor Alirocumab Associated With 75% Reduction in Apheresis

Among patients with heterozygous familial hypercholesterolemia, alirocumab was associated with a 75% reduction in lipoprotein apheresis compared with placebo.

Statins Limit Vaccine Efficacy of Influenza Strain

Statins Limit Vaccine Efficacy of Influenza Strain

Statin use modified vaccine effectiveness and influenza risk for A(H3N2) infection but not for A(H1N1).

Higher Vitamin D Levels May Related to Higher Total Cholesterol, HDL-C

Higher Vitamin D Levels May Related to Higher Total Cholesterol, HDL-C

Vitamin D may influence cardiovascular disease risk via its effect on lipid levels.

Considering Cardiovascular Risks of Antidiabetic Drugs

Considering Cardiovascular Risks of Antidiabetic Drugs

A review of current antidiabetic drug treatments available and their individual cardiovascular risk profiles.

PCSK9 Inhibitors: Breakthrough in LDL-C Reduction, But Comes at a Cost

PCSK9 Inhibitors: Breakthrough in LDL-C Reduction, But Comes at a Cost

PCSK9 inhibitors may offer hope to patients with familial hypercholesterolemia who cannot tolerate or achieve goal LDL-C levels with statins.

LATEST NEWS

Association Between Statins and Depression Likely Mediated by Confounding

Association Between Statins and Depression Likely Mediated by Confounding

The association between statins and depression risk may be mediated by residual confounding or bias.

Tic Disorders Linked to Increased Risk for Cardiometabolic Disease

Tic Disorders Linked to Increased Risk for Cardiometabolic Disease

Patients with Tourette syndrome or chronic tic disorder have an increased risk for developing at least one metabolic or cardiovascular disorder.

Statin Therapy Reduces Risk for Diabetic Retinopathy in Type 2 Diabetes

Statin Therapy Reduces Risk for Diabetic Retinopathy in Type 2 Diabetes

Reduced risk, slowed progression of retinopathy for Taiwanese patients with type 2 diabetes, dyslipidemia

Safety of PCSK9 Inhibitors After Heart Transplantation Examined

Safety of PCSK9 Inhibitors After Heart Transplantation Examined

PCSK9 inhibitors are a potentially safe lipid-lowering therapy for heart transplant recipients with suboptimal LDL management on statins.

Evolocumab Autoinjectors, Pre-Filled Syringes Now Available at Reduced List Price

Evolocumab Autoinjectors, Pre-Filled Syringes Now Available at Reduced List Price

Amgen announced that all Repatha (evolocumab) devices are now available at a 60% reduced list price. This includes the pre-filled syringe, the SureClick autoinjector, and the Pushtronex device, an on-body infusor with prefilled cartridge.

High-Intensity Statins Affect Coronary Plaque Composition After STEMI

High-Intensity Statins Affect Coronary Plaque Composition After STEMI

Patients using a high-intensity statin after a STEMI experienced a significant increase in minimum fibrous cap thickness.

Further Reductions in Alirocumab Price Needed to Be Considered Cost-Effective

Further Reductions in Alirocumab Price Needed to Be Considered Cost-Effective

For alirocumab to be considered cost-effective compared with generic ezetimibe, its annual price would have to be reduced to less than $90.

CVD Risk Factors in Heterozygous Familial Hypercholesterolemia

CVD Risk Factors in Heterozygous Familial Hypercholesterolemia

Smoking, hypertension, and diabetes contributed to more than a quarter of excess CVD risk in individuals with heterozygous familiar hypercholesterolemia.

Hypobetalipoproteinemia Associated With Aggression and Schizophrenia

Hypobetalipoproteinemia Associated With Aggression and Schizophrenia

Study results showed that the prevalence of hypobetalipoproteinemia was 4-fold higher in the psychiatric group compared with the general population.

Serum Cholesterol Efflux Capacity Inversely Associated With Mortality After MI

Serum Cholesterol Efflux Capacity Inversely Associated With Mortality After MI

An integrative marker of the reverse cholesterol transport pathway was inversely associated with all-cause mortality in MI.

Sign Up for Free e-Newsletters